{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T00:06:07Z","timestamp":1759017967336,"version":"3.44.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,9,27]]},"DOI":"10.7759\/cureus.93337","type":"journal-article","created":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T11:19:27Z","timestamp":1758971967000},"source":"Crossref","is-referenced-by-count":0,"title":["Tenapanor for Irritable Bowel Syndrome With Constipation (IBS-C): A Systematic Review of Randomized Trials Assessing Food and Drug Administration (FDA) Composite Response, Durability, and Risk-of-Bias (RoB-2)"],"prefix":"10.7759","author":[{"given":"Abdulkreem","family":"Al-Juhani","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mahmoud S","family":"Desoky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marwah","family":"Nasir Ahmad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abdulrahman","family":"Alharthi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rawiyah A","family":"Alkabkabi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lujain","family":"Suhaqi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jana H","family":"Alzahrani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taif A","family":"Alotibi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fatimah","family":"Almadih","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rodan","family":"Desoky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2017.41","article-title":"Tenapanor treatment of patients with constipation-predominant irritable bowel syndrome: a phase 2, randomized, placebo-controlled efficacy and safety trial","volume":"112","author":"Chey WD","year":"2017","unstructured":"Chey WD, Lembo AJ, Rosenbaum DP. Tenapanor treatment of patients with constipation-predominant irritable bowel syndrome: a phase 2, randomized, placebo-controlled efficacy and safety trial. Am J Gastroenterol. 2017, 112:763-74. 10.1038\/ajg.2017.41","journal-title":"Am J Gastroenterol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.14309\/ajg.0000000000000516","article-title":"Efficacy of Tenapanor in treating patients with irritable bowel syndrome with constipation: a 12-week, placebo-controlled phase 3 trial (T3MPO-1)","volume":"115","author":"Chey WD","year":"2020","unstructured":"Chey WD, Lembo AJ, Rosenbaum DP. Efficacy of Tenapanor in treating patients with irritable bowel syndrome with constipation: a 12-week, placebo-controlled phase 3 trial (T3MPO-1). Am J Gastroenterol. 2020, 115:281-93. 10.14309\/ajg.0000000000000516","journal-title":"Am J Gastroenterol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.14309\/ajg.0000000000001056","article-title":"Efficacy of Tenapanor in treating patients with irritable bowel syndrome with constipation: a 26-week, placebo-controlled phase 3 trial (T3MPO-2)","volume":"116","author":"Chey WD","year":"2021","unstructured":"Chey WD, Lembo AJ, Yang Y, Rosenbaum DP. Efficacy of Tenapanor in treating patients with irritable bowel syndrome with constipation: a 26-week, placebo-controlled phase 3 trial (T3MPO-2). Am J Gastroenterol. 2021, 116:1294-303. 10.14309\/ajg.0000000000001056","journal-title":"Am J Gastroenterol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1111\/nmo.14658","article-title":"Long-term safety of Tenapanor in patients with irritable bowel syndrome with constipation in the T3MPO-3 study","volume":"35","author":"Lembo AJ","year":"2023","unstructured":"Lembo AJ, Friedenberg KA, Fogel RP, et al.. Long-term safety of Tenapanor in patients with irritable bowel syndrome with constipation in the T3MPO-3 study. Neurogastroenterol Motil. 2023, 35:e14658. 10.1111\/nmo.14658","journal-title":"Neurogastroenterol Motil"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.14309\/ajg.0000000000002685","article-title":"Abdominal symptom improvement during clinical trials of Tenapanor in patients with irritable bowel syndrome with constipation: a post hoc analysis","volume":"119","author":"Lembo AJ","year":"2024","unstructured":"Lembo AJ, Chey WD, Harris LA, et al.. Abdominal symptom improvement during clinical trials of Tenapanor in patients with irritable bowel syndrome with constipation: a post hoc analysis. Am J Gastroenterol. 2024, 119:937-45. 10.14309\/ajg.0000000000002685","journal-title":"Am J Gastroenterol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1159\/000543166","article-title":"Tenapanor improves abdominal symptoms irrespective of changes in complete spontaneous bowel movement frequency in adults with irritable bowel syndrome with constipation","volume":"43","author":"Brenner DM","year":"2025","unstructured":"Brenner DM, Sayuk GS, Cash BD, et al.. Tenapanor improves abdominal symptoms irrespective of changes in complete spontaneous bowel movement frequency in adults with irritable bowel syndrome with constipation. Dig Dis. 2025, 43:146-57. 10.1159\/000543166","journal-title":"Dig Dis"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.14309\/ajg.0000000000001036","article-title":"ACG clinical guideline: management of irritable bowel syndrome","volume":"116","author":"Lacy BE","year":"2021","unstructured":"Lacy BE, Pimentel M, Brenner DM, Chey WD, Keefer LA, Long MD, Moshiree B. ACG clinical guideline: management of irritable bowel syndrome. Am J Gastroenterol. 2021, 116:17-44. 10.14309\/ajg.0000000000001036","journal-title":"Am J Gastroenterol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2022.04.016","article-title":"AGA clinical practice guideline on the pharmacological management of irritable bowel syndrome with constipation","volume":"163","author":"Chang L","year":"2022","unstructured":"Chang L, Sultan S, Lembo A, Verne GN, Smalley W, Heidelbaugh JJ. AGA clinical practice guideline on the pharmacological management of irritable bowel syndrome with constipation. Gastroenterology. 2022, 163:118-36. 10.1053\/j.gastro.2022.04.016","journal-title":"Gastroenterology"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2022.04.017","article-title":"AGA clinical practice guideline on the pharmacological management of irritable bowel syndrome with diarrhea","volume":"163","author":"Lembo A","year":"2022","unstructured":"Lembo A, Sultan S, Chang L, Heidelbaugh JJ, Smalley W, Verne GN. AGA clinical practice guideline on the pharmacological management of irritable bowel syndrome with diarrhea. Gastroenterology. 2022, 163:137-51. 10.1053\/j.gastro.2022.04.017","journal-title":"Gastroenterology"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2016.02.031","article-title":"Bowel disorders","author":"Mearin F","year":"2016","unstructured":"Mearin F, Lacy BE, Chang L, Chey WD, Lembo AJ, Simren M, Spiller R. Bowel disorders. Gastroenterology. 2016, 10.1053\/j.gastro.2016.02.031","journal-title":"Gastroenterology"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2016.03.035","article-title":"Rome IV-functional GI disorders: disorders of gut-brain interaction","volume":"150","author":"Drossman DA","year":"2016","unstructured":"Drossman DA, Hasler WL. Rome IV-functional GI disorders: disorders of gut-brain interaction. Gastroenterology. 2016, 150:1257-61. 10.1053\/j.gastro.2016.03.035","journal-title":"Gastroenterology"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2014.09.002","article-title":"American Gastroenterological Association Institute Technical Review on the pharmacological management of irritable bowel syndrome","volume":"147","author":"Chang L","year":"2014","unstructured":"Chang L, Lembo A, Sultan S. American Gastroenterological Association Institute Technical Review on the pharmacological management of irritable bowel syndrome. Gastroenterology. 2014, 147:1149-72.e2. 10.1053\/j.gastro.2014.09.002","journal-title":"Gastroenterology"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1186\/1477-7525-4-79","article-title":"Guidance for industry: patient-reported outcome measures: use in medical product development to support labeling claims: draft guidance","volume":"4","year":"2006","unstructured":"Guidance for industry. patient-reported outcome measures: use in medical product development to support labeling claims: draft guidance. Health Qual Life Outcomes. 2006, 4:79. 10.1186\/1477-7525-4-79","journal-title":"Health Qual Life Outcomes"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2010.04328.x","article-title":"Meta-analysis: factors affecting placebo response rate in the irritable bowel syndrome","volume":"32","author":"Ford AC","year":"2010","unstructured":"Ford AC, Moayyedi P. Meta-analysis: factors affecting placebo response rate in the irritable bowel syndrome. Aliment Pharmacol Ther. 2010, 32:144-58. 10.1111\/j.1365-2036.2010.04328.x","journal-title":"Aliment Pharmacol Ther"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2982.2005.00650.x","article-title":"The placebo effect in irritable bowel syndrome trials: a meta-analysis","volume":"17","author":"Patel SM","year":"2005","unstructured":"Patel SM, Stason WB, Legedza A, et al.. The placebo effect in irritable bowel syndrome trials: a meta-analysis. Neurogastroenterol Motil. 2005, 17:332-40. 10.1111\/j.1365-2982.2005.00650.x","journal-title":"Neurogastroenterol Motil"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(21)00023-6","article-title":"Placebo response rate in pharmacological trials in irritable bowel syndrome: systematic review and meta\u2011analysis","volume":"6","author":"Bosman M","year":"2021","unstructured":"Bosman M, Corsetti M, Keszthelyi D, et al.. Placebo response rate in pharmacological trials in irritable bowel syndrome: systematic review and meta\u2011analysis. Lancet Gastroenterol Hepatol. 2021, 6:459-473. 10.1016\/S2468-1253(21)00023-6","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2021.08.025","article-title":"Placebo response rates in trials of licensed drugs for irritable bowel syndrome with constipation or diarrhea: meta-analysis","volume":"20","author":"Barberio B","year":"2022","unstructured":"Barberio B, Savarino EV, Black CJ, Ford AC. Placebo response rates in trials of licensed drugs for irritable bowel syndrome with constipation or diarrhea: meta-analysis. Clin Gastroenterol Hepatol. 2022, 20:e923-44. 10.1016\/j.cgh.2021.08.025","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2012.254","article-title":"Linaclotide for irritable bowel syndrome with constipation: a 26-week, randomized, double-blind, placebo-controlled trial to evaluate efficacy and safety","volume":"107","author":"Chey WD","year":"2012","unstructured":"Chey WD, Lembo AJ, Lavins BJ, et al.. Linaclotide for irritable bowel syndrome with constipation: a 26-week, randomized, double-blind, placebo-controlled trial to evaluate efficacy and safety. Am J Gastroenterol. 2012, 107:1702-12. 10.1038\/ajg.2012.254","journal-title":"Am J Gastroenterol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1111\/apt.12123","article-title":"Randomised clinical trials: linaclotide phase 3 studies in IBS-C - a prespecified further analysis based on European Medicines Agency-specified endpoints","volume":"37","author":"Quigley EM","year":"2013","unstructured":"Quigley EM, Tack J, Chey WD, et al.. Randomised clinical trials: linaclotide phase 3 studies in IBS-C - a prespecified further analysis based on European Medicines Agency-specified endpoints. Aliment Pharmacol Ther. 2013, 37:49-61. 10.1111\/apt.12123","journal-title":"Aliment Pharmacol Ther"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2008.03881.x","article-title":"Clinical trial: lubiprostone in patients with constipation-associated irritable bowel syndrome--results of two randomized, placebo-controlled studies","volume":"29","author":"Drossman DA","year":"2009","unstructured":"Drossman DA, Chey WD, Johanson JF, Fass R, Scott C, Panas R, Ueno R. Clinical trial: lubiprostone in patients with constipation-associated irritable bowel syndrome--results of two randomized, placebo-controlled studies. Aliment Pharmacol Ther. 2009, 29:329-41. 10.1111\/j.1365-2036.2008.03881.x","journal-title":"Aliment Pharmacol Ther"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1038\/s41395-018-0026-7","article-title":"Efficacy, safety, and tolerability of plecanatide in patients with irritable bowel syndrome with constipation: results of two phase 3 randomized clinical trials","volume":"113","author":"Brenner DM","year":"2018","unstructured":"Brenner DM, Fogel R, Dorn SD, et al.. Efficacy, safety, and tolerability of plecanatide in patients with irritable bowel syndrome with constipation: results of two phase 3 randomized clinical trials. Am J Gastroenterol. 2018, 113:735-45. 10.1038\/s41395-018-0026-7","journal-title":"Am J Gastroenterol"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1016\/j.tips.2021.11.002","article-title":"Guanylate cyclase-C agonists as peripherally acting treatments of chronic visceral pain","volume":"43","author":"Brierley SM","year":"2022","unstructured":"Brierley SM, Grundy L, Castro J, Harrington AM, Hannig G, Camilleri M. Guanylate cyclase-C agonists as peripherally acting treatments of chronic visceral pain. Trends Pharmacol Sci. 2022, 43:110-22. 10.1016\/j.tips.2021.11.002","journal-title":"Trends Pharmacol Sci"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2013.08.017","article-title":"Linaclotide inhibits colonic nociceptors and relieves abdominal pain via guanylate cyclase-C and extracellular cyclic guanosine 3',5'-monophosphate","volume":"145","author":"Castro J","year":"2013","unstructured":"Castro J, Harrington AM, Hughes PA, et al.. Linaclotide inhibits colonic nociceptors and relieves abdominal pain via guanylate cyclase-C and extracellular cyclic guanosine 3',5'-monophosphate. Gastroenterology. 2013, 145:1334-46.e1-11. 10.1053\/j.gastro.2013.08.017","journal-title":"Gastroenterology"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.3389\/fnmol.2014.00031","article-title":"Guanylate cyclase-C\/cGMP: an emerging pathway in the regulation of visceral pain","volume":"7","author":"Hannig G","year":"2014","unstructured":"Hannig G, Tchernychev B, Kurtz CB, Bryant AP, Currie MG, Silos-Santiago I. Guanylate cyclase-C\/cGMP: an emerging pathway in the regulation of visceral pain. Front Mol Neurosci. 2014, 7:31. 10.3389\/fnmol.2014.00031","journal-title":"Front Mol Neurosci"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v24.i17.1888","article-title":"Oral treatment with plecanatide or dolcanatide attenuates visceral hypersensitivity via activation of guanylate cyclase-C in rat models","volume":"24","author":"Boulete IM","year":"2018","unstructured":"Boulete IM, Thadi A, Beaufrand C, et al.. Oral treatment with plecanatide or dolcanatide attenuates visceral hypersensitivity via activation of guanylate cyclase-C in rat models. World J Gastroenterol. 2018, 24:1888-900. 10.3748\/wjg.v24.i17.1888","journal-title":"World J Gastroenterol"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.physiol.67.031103.153004","article-title":"Molecular physiology of intestinal Na+\/H+ exchange","volume":"67","author":"Zachos NC","year":"2005","unstructured":"Zachos NC, Tse M, Donowitz M. Molecular physiology of intestinal Na+\/H+ exchange. Annu Rev Physiol. 2005, 67:411-43. 10.1146\/annurev.physiol.67.031103.153004","journal-title":"Annu Rev Physiol"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3007790","article-title":"Intestinal inhibition of the Na+\/H+ exchanger 3 prevents cardiorenal damage in rats and inhibits Na+ uptake in humans","volume":"6","author":"Spencer AG","year":"2014","unstructured":"Spencer AG, Labonte ED, Rosenbaum DP, et al.. Intestinal inhibition of the Na+\/H+ exchanger 3 prevents cardiorenal damage in rats and inhibits Na+ uptake in humans. Sci Transl Med. 2014, 6:227ra36. 10.1126\/scitranslmed.3007790","journal-title":"Sci Transl Med"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2018080832","article-title":"Efficacy and safety of Tenapanor in patients with hyperphosphatemia receiving maintenance hemodialysis: a randomized phase 3 trial","volume":"30","author":"Block GA","year":"2019","unstructured":"Block GA, Rosenbaum DP, Yan A, Chertow GM. Efficacy and safety of Tenapanor in patients with hyperphosphatemia receiving maintenance hemodialysis: a randomized phase 3 trial. J Am Soc Nephrol. 2019, 30:641-52. 10.1681\/ASN.2018080832","journal-title":"J Am Soc Nephrol"},{"key":"ref29","article-title":"Guanylate cyclase\u2011C as a therapeutic target in gastrointestinal disorders","volume":"148","author":"Waldman SA","year":"2015","unstructured":"Waldman SA, Camilleri M. Guanylate cyclase\u2011C as a therapeutic target in gastrointestinal disorders. Gastroenterology. 2015, 148:698-701.","journal-title":"Gastroenterology"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1172\/JCI76304","article-title":"Gut\/brain axis and the microbiota","volume":"125","author":"Mayer EA","year":"2015","unstructured":"Mayer EA, Tillisch K, Gupta A. Gut\/brain axis and the microbiota. J Clin Invest. 2015, 125:926-38. 10.1172\/JCI76304","journal-title":"J Clin Invest"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2013.09.046","article-title":"A diet low in FODMAPs reduces symptoms of irritable bowel syndrome","volume":"146","author":"Halmos EP","year":"2014","unstructured":"Halmos EP, Power VA, Shepherd SJ, Gibson PR, Muir JG. A diet low in FODMAPs reduces symptoms of irritable bowel syndrome. Gastroenterology. 2014, 146:67-75.e5. 10.1053\/j.gastro.2013.09.046","journal-title":"Gastroenterology"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2015.07.054","article-title":"Diet low in FODMAPs reduces symptoms of irritable bowel syndrome as well as traditional dietary advice: a randomized controlled trial","volume":"149","author":"B\u00f6hn L","year":"2015","unstructured":"B\u00f6hn L, St\u00f6rsrud S, Liljebo T, Collin L, Lindfors P, T\u00f6rnblom H, Simr\u00e9n M. Diet low in FODMAPs reduces symptoms of irritable bowel syndrome as well as traditional dietary advice: a randomized controlled trial. Gastroenterology. 2015, 149:1399-1407.e2. 10.1053\/j.gastro.2015.07.054","journal-title":"Gastroenterology"},{"key":"ref33","article-title":"Global prevalence of irritable bowel syndrome: systematic review and meta\u2011analysis","volume":"158","author":"Oka P","year":"2020","unstructured":"Oka P, Parr H, Barberio B, et al.. Global prevalence of irritable bowel syndrome: systematic review and meta\u2011analysis. Gastroenterology. 2020, 158:1262-1280.","journal-title":"Gastroenterology"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2021.04.043","article-title":"Natural history and disease impact of Rome IV Vs Rome III irritable bowel syndrome: a longitudinal follow-up study","volume":"20","author":"Goodoory VC","year":"2022","unstructured":"Goodoory VC, Houghton LA, Yiannakou Y, Black CJ, Ford AC. Natural history and disease impact of Rome IV Vs Rome III irritable bowel syndrome: a longitudinal follow-up study. Clin Gastroenterol Hepatol. 2022, 20:569-577.e3. 10.1016\/j.cgh.2021.04.043","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1023\/a:1018831127942","article-title":"Quality of life in persons with irritable bowel syndrome: development and validation of a new measure","volume":"43","author":"Patrick DL","year":"1998","unstructured":"Patrick DL, Drossman DA, Frederick IO, DiCesare J, Puder KL. Quality of life in persons with irritable bowel syndrome: development and validation of a new measure. Dig Dis Sci. 1998, 43:400-11. 10.1023\/a:1018831127942","journal-title":"Dig Dis Sci"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.1997.142318000.x","article-title":"The irritable bowel severity scoring system: a simple method of monitoring irritable bowel syndrome and its progress","volume":"11","author":"Francis CY","year":"1997","unstructured":"Francis CY, Morris J, Whorwell PJ. The irritable bowel severity scoring system: a simple method of monitoring irritable bowel syndrome and its progress. Aliment Pharmacol Ther. 1997, 11:395-402. 10.1046\/j.1365-2036.1997.142318000.x","journal-title":"Aliment Pharmacol Ther"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.2196\/19696","article-title":"Smart data collection for the assessment of treatment effects in irritable bowel syndrome: observational study","volume":"8","author":"Weerts ZZ","year":"2020","unstructured":"Weerts ZZ, Heinen KG, Masclee AA, et al.. Smart data collection for the assessment of treatment effects in irritable bowel syndrome: observational study. JMIR Mhealth Uhealth. 2020, 8:e19696. 10.2196\/19696","journal-title":"JMIR Mhealth Uhealth"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne JA","year":"2019","unstructured":"Sterne JA, Savovi\u0107 J, Page MJ, et al.. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019, 366:l4898. 10.1136\/bmj.l4898","journal-title":"BMJ"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1016\/j.jclinepi.2010.04.026","article-title":"GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables","volume":"64","author":"Guyatt G","year":"2011","unstructured":"Guyatt G, Oxman AD, Akl EA, et al.. GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. J Clin Epidemiol. 2011, 64:383-94. 10.1016\/j.jclinepi.2010.04.026","journal-title":"J Clin Epidemiol"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2019.12.021","article-title":"Prevalence of Rome IV functional bowel disorders among adults in the United States, Canada, and the United Kingdom","volume":"158","author":"Palsson OS","year":"2020","unstructured":"Palsson OS, Whitehead W, T\u00f6rnblom H, Sperber AD, Simren M. Prevalence of Rome IV functional bowel disorders among adults in the United States, Canada, and the United Kingdom. Gastroenterology. 2020, 158:1262-1273.e3. 10.1053\/j.gastro.2019.12.021","journal-title":"Gastroenterology"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2015.0954","article-title":"Irritable bowel syndrome: a clinical review","volume":"313","author":"Chey WD","year":"2015","unstructured":"Chey WD, Kurlander J, Eswaran S. Irritable bowel syndrome: a clinical review. JAMA. 2015, 313:949-58. 10.1001\/jama.2015.0954","journal-title":"JAMA"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2014.20.4.382","article-title":"Economic burden of irritable bowel syndrome with constipation: a retrospective analysis of health care costs in a commercially insured population","volume":"20","author":"Doshi JA","year":"2014","unstructured":"Doshi JA, Cai Q, Buono JL, et al.. Economic burden of irritable bowel syndrome with constipation: a retrospective analysis of health care costs in a commercially insured population. J Manag Care Spec Pharm. 2014, 20:382-90. 10.18553\/jmcp.2014.20.4.382","journal-title":"J Manag Care Spec Pharm"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1186\/s12876-019-0985-1","article-title":"Economic burden of moderate to severe irritable bowel syndrome with constipation in six European countries","volume":"19","author":"Tack J","year":"2019","unstructured":"Tack J, Stanghellini V, Mearin F, et al.. Economic burden of moderate to severe irritable bowel syndrome with constipation in six European countries. BMC Gastroenterol. 2019, 19:69. 10.1186\/s12876-019-0985-1","journal-title":"BMC Gastroenterol"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1038\/s41588-021-00950-8","article-title":"Genome-wide analysis of 53,400 people with irritable bowel syndrome highlights shared genetic pathways with mood and anxiety disorders","volume":"53","author":"Eijsbouts C","year":"2021","unstructured":"Eijsbouts C, Zheng T, Kennedy NA, et al.. Genome-wide analysis of 53,400 people with irritable bowel syndrome highlights shared genetic pathways with mood and anxiety disorders. Nat Genet. 2021, 53:1543-52. 10.1038\/s41588-021-00950-8","journal-title":"Nat Genet"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/411587-tenapanor-for-irritable-bowel-syndrome-with-constipation-ibs-c-a-systematic-review-of-randomized-trials-assessing-food-and-drug-administration-fda-composite-response-durability-and-risk-of-bias-rob-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T11:19:28Z","timestamp":1758971968000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/411587-tenapanor-for-irritable-bowel-syndrome-with-constipation-ibs-c-a-systematic-review-of-randomized-trials-assessing-food-and-drug-administration-fda-composite-response-durability-and-risk-of-bias-rob-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,27]]},"references-count":44,"URL":"https:\/\/doi.org\/10.7759\/cureus.93337","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9,27]]}}}